The UK and US have hammered out a significant bilateral deal that will ensure zero import taxes on British medicine shipments being sold in the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase spending on pharmaceuticals through the National Health Service (NHS). This move ensures that import taxes on these key goods will stay at nothing for a period of the next three years.
This development follows previous threats to dramatically increase tariffs on branded pharmaceutical products, with potential rates mentioned up to one hundred percent.
"This agreement with the United Kingdom reinforces the global environment for innovative medicines and establishes much-needed equity to American-British pharmaceutical trade," a statement declared.
Commercial Importance
Pharmaceuticals are one of the the United Kingdom's largest export categories to the US, which is clearly the biggest market for major British pharmaceutical firms.
Export figures show that in the 12 months leading up to the third quarter, the UK exported drugs totaling billions to the US. This amount made up nearly one-fifth of all goods exports in that span.
"This guarantee secures work, increases capital expenditure and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary remarked.
Key British Pledges
The agreement entails several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to increase total public funding on treatments from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount manufacturers must refund to the NHS to stay within budget will be capped at 15%. Last year, rebates topped twenty percent.
Recent Tensions
This agreement follows a protracted row between the sector and the British authorities over spending levels and regulatory access.
This friction were exacerbated by arguments that US customers were paying a premium for the equivalent treatments than patients in the other developed nations.
In recent months, several major pharmaceutical investments in the UK have been delayed or cancelled, while major funding commitments have been directed toward US facilities.
The Science Minister acknowledged that the NHS must spend more on treatments, noting that its expenditure on drugs had declined as a proportion of its resources over the last ten years.
